SCYNEXIS Q1 net loss $5.5M; BREXAFEMME sales $0.7M; CANDLE study positive for rVVC

SCYNEXIS INC

2022-Q1 EPS reported -$0.18 revenue$687,000

Net loss $5.5M ($0.17/share) vs $4.7M ($0.18) in Q1 2021; product revenue $0.7M from BREXAFEMME.
Cash $95.2M at March 31; plus $42M net from April offering; runway into Q1 2024.
BREXAFEMME: ~4,000 prescriptions Q1, 1,800 HCPs; 55% commercial coverage (93M lives).
CANDLE Phase 3 met endpoint: 65.4% vs 53.1% placebo (p=0.02) for rVVC prevention; sNDA planned Q2 2022.
MARIO global Phase 3 initiated for invasive candidiasis; first patient enrollment expected Q2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.